{"id":"https://genegraph.clinicalgenome.org/r/bef5fa02-9809-43de-9054-74fa9d6a46e1v1.1","type":"EvidenceStrengthAssertion","dc:description":"The relationship between DYSF and limb girdle muscular dystrophy (LGMD; also known as LGMD 2B, LGMD R2 and generally as dysferlinopathy) inherited in the autosomal recessive pattern has been evaluated using the ClinGen Clinical Validity Framework as of April, 2020. This association was made using case-level and experimental data. The DYSF gene is located on chromosome 2p13.2 and encodes multiple transcript variants. The most commonly used transcript is 6.7 kb long with 55 exons encoding a 2080-amino acid protein. More than 200 pathogenic variants reported in humans with autosomal recessive LGMD are recorded in ClinVar, ranging from small deletions and duplications, nonsense, frameshift and splicing to missense variants. In addition to ClinVar and LOVD, the UMD-DYSF database hosts an extensive list of DYSF variants (http://www.umd.be/DYSF/W_DYSF/mutation.html). Limb girdle muscular dystrophy is characterized by progressive weakness in muscles including but not limited to the proximal muscles, and affecting the pelvic and shoulder girdle which can lead to difficulty walking or complete loss of ambulation requiring wheelchair use. It is also accompanied by an elevated serum creatine kinase. DYSF has been reported in association with autosomal recessive LGMD as early as 1998 by Liu et al and Bashir et al (PMIDs: 9731526, 9731527). Summary of Case Level Data (12 points): The association is seen in at least 16 probands in 7 publications (PMID: 9731526, 16010686, 21522182, 14678801, 17825554, 16087766, 10196377). Variants in this gene segregated with disease in 8 additional family members. More case-level evidence is available in the literature, but the maximum score for genetic evidence (12 pts) has been reached. The mechanism for disease has been reported to be biallelic loss of function. Summary of Experimental Data (6 points): This gene-disease relationship is supported by animal models, expression studies, functional assays and rescue evidence. Dysferlin has a role in sarcolemmal repair and T-tubule organization (PMID: 12736685, 24302765, 28104817). It is strongly expressed in skeletal muscles and localizes to the membrane (PMID: 10196375). Dysferlin has multiple protein interaction partners (PMID: 11532985, 21079765). A number of mouse models (PMID: 23473732, 15254015, 12736685) and rescue in mouse models and patient cells (PMID: 27858744, 20861509, 19834057, 28707952, 31890729, 31019989) are also reported. In summary, the DYSF-autosomal recessive limb-girdle muscular dystrophy gene-disease relationship is definitive. This has been repeatedly demonstrated in both research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Limb-Girdle Muscular Dystrophy GCEP on 4/14/20 (SOP Version 7). \n\nThis gene curation was re-approved and published on 11/14/24 by the Muscular Dystrophies and Myopathies GCEP to reflect the change in the panel's name from LGMD GCEP to MDM GCEP. As part of this process, the genetic evidence was re-scored in accordance with SOP version 11.\n\nLumping & Splitting Consideration: OMIM disease entities: Miyoshi muscular dystrophy 1 (254130); Muscular dystrophy, limb-girdle, autosomal recessive 2 (253601); Myopathy, distal, with anterior tibial onset (606768). Variants in DYSF have been described in individuals with additional phenotypes including scapulo-peroneal myopathy, pseudo-metabolic myopathy, asymptomatic hyperCKemia,, and even congenital onset  Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism(s) AND inheritance pattern AND phenotypic variability in the above mentioned disease entities. Therefore, all of the disease entities have been lumped into one disease entity, autosomal recessive limb girdle muscular dystrophy (MONDO:0015152).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/bef5fa02-9809-43de-9054-74fa9d6a46e1","GCISnapshot":"https://genegraph.clinicalgenome.org/r/94042756-2e7a-4cfa-812c-1b88b703eeea","calculatedEvidenceStrength":"Definitive","changes":[{"id":"cg:otherTextChange"},{"id":"cg:sopChange"},{"id":"cg:summaryChange"},{"id":"cg:expertPanelChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/94042756-2e7a-4cfa-812c-1b88b703eeea_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10151","date":"2024-11-14T20:11:56.689Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/94042756-2e7a-4cfa-812c-1b88b703eeea_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10151","date":"2024-11-14T17:00:00.000Z","role":"Approver"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94042756-2e7a-4cfa-812c-1b88b703eeea_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a689466f-7838-49fe-88d3-c49fdaf558d9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a689466f-7838-49fe-88d3-c49fdaf558d9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14678801","rdfs:label":"Cagliani_IV-1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":27,"allele":{"id":"https://genegraph.clinicalgenome.org/r/0cdf9913-2e53-4ce7-859d-a77a8c0e3e8f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.2929C>T (p.Arg977Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1706331"}},"detectionMethod":"Sanger, confirmed in cDNA by RT-PCR. In order to rule out the presence of a deletion on the other allele, FISH was performed.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Onset at 27y. CK 5737 IU/l. ECG demonstrated aspecific ventricular repolarization alterations","phenotypes":["obo:HP_0003551","obo:HP_0003749","obo:HP_0007340","obo:HP_0003115","obo:HP_0030234","obo:HP_0030115","obo:HP_0003458","obo:HP_0003560","obo:HP_0012514"],"previousTesting":false,"secondTestingMethod":"Other","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/547ba12e-d050-400d-bad2-0385cec50aeb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14678801","allele":{"id":"https://genegraph.clinicalgenome.org/r/0cdf9913-2e53-4ce7-859d-a77a8c0e3e8f"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/547ba12e-d050-400d-bad2-0385cec50aeb","type":"EvidenceLine","dc:description":"missense with functional support (no downgrade for homozygosity)","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/547ba12e-d050-400d-bad2-0385cec50aeb_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/547ba12e-d050-400d-bad2-0385cec50aeb_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 28104817","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/31acbcd6-4810-4369-a6f7-dcc1c7957068_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/31acbcd6-4810-4369-a6f7-dcc1c7957068","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","rdfs:label":"Nguyen_dysDAR","allele":{"id":"https://genegraph.clinicalgenome.org/r/1dfbbb0c-3599-46a5-84ff-dc6cd79a388b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XR_001738969.1(DYSF):n.2049_2053dup","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA915941060"}},"detectionMethod":"DNA extracted from peripheral blood lymphocytes was subject to PCR. All 55 exons including flanking regions were amplified. SSCP and dHPLC were used to detect abnormal products which were directly sequenced.","firstTestingMethod":"SSCP","phenotypes":"obo:HP_0002460","previousTesting":true,"previousTestingDescription":"Patients were recruited to this study if their clinical phenotype was consistent with LGMD or distal myopathy. Loss or strong reduction of dysferlin expression evidenced by Western-blotting and/or immunohistochemistry on muscle biopsy was confirmed. If biopsy was unavailable, dysferlin deficiency in the sibship, and/or linkage to chromosome 2p13 was confirmed.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/7062e5f7-b004-45bd-8c55-8e8ae2f30778_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","allele":{"id":"https://genegraph.clinicalgenome.org/r/1dfbbb0c-3599-46a5-84ff-dc6cd79a388b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/7062e5f7-b004-45bd-8c55-8e8ae2f30778","type":"EvidenceLine","dc:description":"NMD expected, downgraded for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7062e5f7-b004-45bd-8c55-8e8ae2f30778_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/f907d832-4012-43f8-9a51-13f6de17724e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f907d832-4012-43f8-9a51-13f6de17724e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14678801","rdfs:label":"Cagliani_I-1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":14,"allele":{"id":"https://genegraph.clinicalgenome.org/r/1d75da03-d6bf-407f-a96c-a1376d632cdd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XR_001738969.1(DYSF):n.5378_5380del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA915940975"}},"detectionMethod":"The entire DYSF gene was sequenced. The impact on splicing was confirmed by RT-PCR","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The onset was at 14yo, with the loss of independent walking at the age of 46 years. The phenotype was most consistent with a distal myopathy at the disease onset, to evolve toward a proximal and distal muscle involvement 10 years later. CK >3000UI/L","phenotypes":["obo:HP_0003560","obo:HP_0003547","obo:HP_0001771","obo:HP_0003458","obo:HP_0002359","obo:HP_0001284","obo:HP_0009027","obo:HP_0030114","obo:HP_0007340","obo:HP_0002540","obo:HP_0003202","obo:HP_0030234"],"previousTesting":false,"secondTestingMethod":"Restriction digest","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/16ac3ad9-6d00-45aa-9403-4ce2e33e2890_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14678801","allele":{"id":"https://genegraph.clinicalgenome.org/r/1d75da03-d6bf-407f-a96c-a1376d632cdd"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/16ac3ad9-6d00-45aa-9403-4ce2e33e2890","type":"EvidenceLine","dc:description":"splice variant with confirmed absent protein in patient muscle, downgraded for homozygosity","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/16ac3ad9-6d00-45aa-9403-4ce2e33e2890_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/16ac3ad9-6d00-45aa-9403-4ce2e33e2890_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The splicing defect of this variant was confirmed by RT-PCR. No dysferlin protein is present Western Blot on muscle biopsy. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/245d9ccc-72d5-4cb4-9635-b61feaf3be87_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/245d9ccc-72d5-4cb4-9635-b61feaf3be87","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","rdfs:label":"Nguyen_dysGH","allele":{"id":"https://genegraph.clinicalgenome.org/r/12e4b5d0-ce95-4a80-a2c6-2b1c699a435f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XR_001738969.1(DYSF):n.3289G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347216891"}},"detectionMethod":"DNA extracted from peripheral blood lymphocytes was subject to PCR. All 55 exons including flanking regions were amplified. SSCP and dHPLC were used to detect abnormal products which were directly sequenced.","firstTestingMethod":"SSCP","phenotypes":"obo:HP_0003701","previousTesting":true,"previousTestingDescription":"Patients were recruited to this study if their clinical phenotype was consistent with LGMD or distal myopathy. Loss or strong reduction of dysferlin expression evidenced by Western-blotting and/or immunohistochemistry on muscle biopsy was confirmed. If biopsy was unavailable, dysferlin deficiency in the sibship, and/or linkage to chromosome 2p13 was confirmed.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/16914815-46ad-4373-984c-2f97b235b6b5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","allele":{"id":"https://genegraph.clinicalgenome.org/r/12e4b5d0-ce95-4a80-a2c6-2b1c699a435f"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/16914815-46ad-4373-984c-2f97b235b6b5","type":"EvidenceLine","dc:description":"NMD expected, downgraded for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/16914815-46ad-4373-984c-2f97b235b6b5_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/787550ee-253e-4211-8bb1-ca1e593fdbb4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/787550ee-253e-4211-8bb1-ca1e593fdbb4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9731526","rdfs:label":"Liu_Family 59 Proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/5a642065-697b-4734-a260-adcf8094c494","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.167dup (p.Ile58HisfsTer8)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA279067"}},"detectionMethod":"SSCP was performed to identify abnormal conformers, which were subsequently sequenced to detect the variants. In patients from whom a muscle biopsy sample was available, RT-PCR was performed to detect mutations.","firstTestingMethod":"SSCP","phenotypeFreeText":"The proband is noted to have Miyoshi myopathy","phenotypes":"obo:HP_0006785","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/ee36baf4-b2ff-48b4-825d-0dd5ddddfd77_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9731526","allele":{"id":"https://genegraph.clinicalgenome.org/r/5a642065-697b-4734-a260-adcf8094c494"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/ee36baf4-b2ff-48b4-825d-0dd5ddddfd77","type":"EvidenceLine","dc:description":"NMD expected, downgraded for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ee36baf4-b2ff-48b4-825d-0dd5ddddfd77_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ead626f7-fb61-4d84-998d-52e81b9b365a_proband_score_evidence_line","type":"EvidenceLine","direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ead626f7-fb61-4d84-998d-52e81b9b365a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9731526","rdfs:label":"Liu_Family 56 Proband","allele":[{"id":"https://genegraph.clinicalgenome.org/r/91054615-2d12-436e-a93d-6fa983293ffc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.3946A>G (p.Ile1316Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA179991"}},{"id":"https://genegraph.clinicalgenome.org/r/a00db8b2-7719-4d5b-9f3e-2ad5a273904f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.6241C>T (p.Arg2081Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA222203"}}],"detectionMethod":"SSCP was performed to identify abnormal conformers, which were subsequently sequenced to detect the variants. In patients from whom a muscle biopsy sample was available, RT-PCR was performed to detect mutations.","firstTestingMethod":"SSCP","phenotypes":["obo:HP_0003701","obo:HP_0002460"],"secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/94bf19e6-12a8-4a77-9b63-f5e3d68998ce_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9731526","allele":{"id":"https://genegraph.clinicalgenome.org/r/91054615-2d12-436e-a93d-6fa983293ffc"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/f1263e3f-01e2-4d82-b113-3728b9735797_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9731526","allele":{"id":"https://genegraph.clinicalgenome.org/r/a00db8b2-7719-4d5b-9f3e-2ad5a273904f"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/94bf19e6-12a8-4a77-9b63-f5e3d68998ce","type":"EvidenceLine","dc:description":"The Ile1316Val variant is reported at a frequency of 0.007128 (912/127946 non-Finnish European alleles) with 6 homozygotes in gnomAD v2.1.1 and is asserted benign. Subsequent analysis in the family identified a splice site variant (unpublished data) that may be the other causative variant, in addition to the Arg2081Cys missense variant. However, in the absence of additional information on the second variant, the proband is not scored.","calculatedScore":0.1,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94bf19e6-12a8-4a77-9b63-f5e3d68998ce_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f1263e3f-01e2-4d82-b113-3728b9735797","type":"EvidenceLine","dc:description":"The Arg2081Cys variant is reported at a frequency of 0.00005274 (6/113770 non-Finnish European alleles) with 0 homozygotes in gnomAD v2.1.1. ","calculatedScore":0.1,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f1263e3f-01e2-4d82-b113-3728b9735797_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f3fe2716-e39e-45ba-b960-906df9464868_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3fe2716-e39e-45ba-b960-906df9464868","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16087766","rdfs:label":"Vilchez_C5","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":18,"allele":{"id":"https://genegraph.clinicalgenome.org/r/08a60770-2f3e-4a39-b9bd-315e101976e0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.5830C>T (p.Arg1944Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA118412"}},"detectionMethod":"SSCP screen followed by Sanger sequencing of exons with abnormal migration pattern","firstTestingMethod":"SSCP","phenotypeFreeText":"Age of onset 18yo. Patient had features of Distal Anterior Dysferlinopathy. The presenting symptom was steppage gait, the initial muscle involved was distal anterior compartment. The progression of symptoms over 20 years included mild involvement of proximal upper and lower limbs. CK level was 5400U/L","phenotypes":["obo:HP_0006785","obo:HP_0030114","obo:HP_0007340","obo:HP_0003458","obo:HP_0030234","obo:HP_0003701","obo:HP_0003376"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/9213bd32-be95-4542-ac23-4229cc10709a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16087766","allele":{"id":"https://genegraph.clinicalgenome.org/r/08a60770-2f3e-4a39-b9bd-315e101976e0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/9213bd32-be95-4542-ac23-4229cc10709a","type":"EvidenceLine","dc:description":"NMD expected, downgraded for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9213bd32-be95-4542-ac23-4229cc10709a_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/5177c7a5-21ec-4eb4-b146-eb3b1621db8b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5177c7a5-21ec-4eb4-b146-eb3b1621db8b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10196377","rdfs:label":"Weiler_probandA8","allele":{"id":"https://genegraph.clinicalgenome.org/r/00ebdcbb-3d33-49fa-ac90-75c7ff9b9a7c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.2426C>G (p.Pro809Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA222139"}},"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/a572a419-e369-4309-ae39-c9622bd1a090_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10196377","allele":{"id":"https://genegraph.clinicalgenome.org/r/00ebdcbb-3d33-49fa-ac90-75c7ff9b9a7c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/a572a419-e369-4309-ae39-c9622bd1a090","type":"EvidenceLine","dc:description":"homozygous missense without functional data","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a572a419-e369-4309-ae39-c9622bd1a090_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/f7ab515d-255e-4d6d-895e-550ac7d59214_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7ab515d-255e-4d6d-895e-550ac7d59214","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21522182","rdfs:label":"Cacciottolo_2122","allele":{"id":"https://genegraph.clinicalgenome.org/r/fdb3bc7d-ee48-42cd-8e7f-aa3ca1af15ed","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.5419C>T (p.Arg1807Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1707356"}},"detectionMethod":"DHPLC screen followed by sequencing of abnormal exons.","firstTestingMethod":"Denaturing gradient gel","phenotypeFreeText":"Dysferlin is reduced to 20% of normal level based on Western","phenotypes":["obo:HP_0030234","obo:HP_0030115"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/b89ee83b-2249-4325-a0b4-fa4443586613_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21522182","allele":{"id":"https://genegraph.clinicalgenome.org/r/fdb3bc7d-ee48-42cd-8e7f-aa3ca1af15ed"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/b89ee83b-2249-4325-a0b4-fa4443586613","type":"EvidenceLine","dc:description":"homozygous missense without functional data","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b89ee83b-2249-4325-a0b4-fa4443586613_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/ffad06c6-0990-4dcc-bd65-b4d99fb491d6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ffad06c6-0990-4dcc-bd65-b4d99fb491d6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","rdfs:label":"Nguyen_dysLA","allele":{"id":"https://genegraph.clinicalgenome.org/r/f43d3f88-1339-4cbf-9041-162a07ab7533","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.5711del (p.Gly1904AlafsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA212859"}},"detectionMethod":"DNA extracted from peripheral blood lymphocytes was subject to PCR. All 55 exons including flanking regions were amplified. SSCP and dHPLC were used to detect abnormal products which were directly sequenced.","firstTestingMethod":"SSCP","phenotypes":["obo:HP_0003701","obo:HP_0002460"],"previousTesting":true,"previousTestingDescription":"Patients were recruited to this study if their clinical phenotype was consistent with LGMD or distal myopathy. Loss or strong reduction of dysferlin expression evidenced by Western-blotting and/or immunohistochemistry on muscle biopsy was confirmed. If biopsy was unavailable, dysferlin deficiency in the sibship, and/or linkage to chromosome 2p13 was confirmed.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/06dfdefc-34a3-4132-a497-39a6c2fc1ad1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","allele":{"id":"https://genegraph.clinicalgenome.org/r/f43d3f88-1339-4cbf-9041-162a07ab7533"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/06dfdefc-34a3-4132-a497-39a6c2fc1ad1","type":"EvidenceLine","dc:description":"NMD expected, downgraded for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/06dfdefc-34a3-4132-a497-39a6c2fc1ad1_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1b043b48-24c0-4aef-9683-2100f8035560_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1b043b48-24c0-4aef-9683-2100f8035560","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","rdfs:label":"Nguyen_dysAL","allele":{"id":"https://genegraph.clinicalgenome.org/r/3a57c01c-6a54-4bff-82be-0c88261f6d89","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XR_001738969.1(DYSF):n.3112dup","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA915941059"}},"detectionMethod":"DNA extracted from peripheral blood lymphocytes was subject to PCR. All 55 exons including flanking regions were amplified. SSCP and dHPLC were used to detect abnormal products which were directly sequenced.","firstTestingMethod":"SSCP","phenotypes":"obo:HP_0003701","previousTesting":true,"previousTestingDescription":"Patients were recruited to this study if their clinical phenotype was consistent with LGMD or distal myopathy. Loss or strong reduction of dysferlin expression evidenced by Western-blotting and/or immunohistochemistry on muscle biopsy was confirmed. If biopsy was unavailable, dysferlin deficiency in the sibship, and/or linkage to chromosome 2p13 was confirmed.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/2be3177d-6b7c-491c-be51-e1762e417005_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","allele":{"id":"https://genegraph.clinicalgenome.org/r/3a57c01c-6a54-4bff-82be-0c88261f6d89"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/2be3177d-6b7c-491c-be51-e1762e417005","type":"EvidenceLine","dc:description":"NMD expected, downgraded for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2be3177d-6b7c-491c-be51-e1762e417005_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/abe0d1dd-d84a-4c30-90b1-7d1d1bf20201_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/abe0d1dd-d84a-4c30-90b1-7d1d1bf20201","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21522182","rdfs:label":"Cacciottolo_3022","allele":{"id":"https://genegraph.clinicalgenome.org/r/5db7065f-e5d9-4162-ae16-966ded7625d5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.334C>T (p.Gln112Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10588346"}},"detectionMethod":"DHPLC screen followed by Sanger sequencing of the abnormal exon","firstTestingMethod":"Denaturing gradient gel","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/48f0785c-8992-43ac-944d-ea001cd77621_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21522182","allele":{"id":"https://genegraph.clinicalgenome.org/r/5db7065f-e5d9-4162-ae16-966ded7625d5"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/48f0785c-8992-43ac-944d-ea001cd77621","type":"EvidenceLine","dc:description":"NMD expected, downgraded for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/48f0785c-8992-43ac-944d-ea001cd77621_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/5c901190-9d7c-48df-b9e4-ad847519cf14_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5c901190-9d7c-48df-b9e4-ad847519cf14","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","rdfs:label":"Nguyen_dysLE","allele":{"id":"https://genegraph.clinicalgenome.org/r/7eaa37f6-704e-4e34-9406-81808df7ac98","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.853C>T (p.Arg285Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1705479"}},"detectionMethod":"DNA extracted from peripheral blood lymphocytes was subject to PCR. All 55 exons including flanking regions were amplified. SSCP and dHPLC were used to detect abnormal products which were directly sequenced.","firstTestingMethod":"SSCP","phenotypeFreeText":"Isolated hyperCKemia","phenotypes":"obo:HP_0003236","previousTesting":true,"previousTestingDescription":"Patients were recruited to this study if their clinical phenotype was consistent with LGMD or distal myopathy. Loss or strong reduction of dysferlin expression evidenced by Western-blotting and/or immunohistochemistry on muscle biopsy was confirmed. If biopsy was unavailable, dysferlin deficiency in the sibship, and/or linkage to chromosome 2p13 was confirmed.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/fc73b430-a19f-4447-961c-fdaeb073d408_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","allele":{"id":"https://genegraph.clinicalgenome.org/r/7eaa37f6-704e-4e34-9406-81808df7ac98"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/fc73b430-a19f-4447-961c-fdaeb073d408","type":"EvidenceLine","dc:description":"homozygous missense without functional data","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fc73b430-a19f-4447-961c-fdaeb073d408_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/54b79508-ddee-4745-a317-e8c7b8569fbc_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/54b79508-ddee-4745-a317-e8c7b8569fbc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17825554","rdfs:label":"Leshinsky-Silver_pt1","allele":{"id":"https://genegraph.clinicalgenome.org/r/6627b23b-f1c3-4445-9714-d34b8402745c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.2833del (p.Ala945LeufsTer21)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA233930"}},"detectionMethod":"Sanger sequencing of all exons, variant confirmed by missmatch-PCR/RLFP. For the rest of the patients with this variant, only missmatch-PCR/RLFP was performed.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0007340","obo:HP_0030234","obo:HP_0003701","obo:HP_0030114"],"previousTesting":false,"secondTestingMethod":"Restriction digest","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/bf85f6bb-45f8-4fbe-8936-8d8fc68644c1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17825554","allele":{"id":"https://genegraph.clinicalgenome.org/r/6627b23b-f1c3-4445-9714-d34b8402745c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/bf85f6bb-45f8-4fbe-8936-8d8fc68644c1","type":"EvidenceLine","dc:description":"NMD expected, downgraded for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bf85f6bb-45f8-4fbe-8936-8d8fc68644c1_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/2200f272-57d4-4087-9939-dbb8554dde87_proband_score_evidence_line","type":"EvidenceLine","direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2200f272-57d4-4087-9939-dbb8554dde87","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9731526","rdfs:label":"Liu_Family 71 Proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/f43d3f88-1339-4cbf-9041-162a07ab7533"},"detectionMethod":"SSCP was performed to identify abnormal conformers, which were subsequently sequenced to detect the variants. In patients from whom a muscle biopsy sample was available, RT-PCR was performed to detect mutations.","firstTestingMethod":"SSCP","phenotypeFreeText":"Proband noted to have distal myopathy with anterior tibial onset","phenotypes":"obo:HP_0006785","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/166a6423-a843-4e38-8c17-1596a2092711_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9731526","allele":{"id":"https://genegraph.clinicalgenome.org/r/f43d3f88-1339-4cbf-9041-162a07ab7533"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/166a6423-a843-4e38-8c17-1596a2092711","type":"EvidenceLine","dc:description":"The proband has been scored in PMID: 16010686, and not scored again here.","calculatedScore":3.0,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/166a6423-a843-4e38-8c17-1596a2092711_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/2c249a46-45a7-4784-8af0-488c68dfee23_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2c249a46-45a7-4784-8af0-488c68dfee23","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9731526","rdfs:label":"Liu_Family 67 Proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/777c4ac3-eb06-4f0c-8245-a9ef38b98cb6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.1867C>T (p.Gln623Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA253901"}},"detectionMethod":"SSCP was performed to identify abnormal conformers, which were subsequently sequenced to detect the variants. In patients from whom a muscle biopsy sample was available, RT-PCR was performed to detect mutations.","firstTestingMethod":"SSCP","phenotypeFreeText":"The proband is noted to have Miyoshi myopathy","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/6b62fe67-c624-4fed-8ada-f20941f8eaca_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9731526","allele":{"id":"https://genegraph.clinicalgenome.org/r/777c4ac3-eb06-4f0c-8245-a9ef38b98cb6"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/6b62fe67-c624-4fed-8ada-f20941f8eaca","type":"EvidenceLine","dc:description":"NMD expected, downgraded for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b62fe67-c624-4fed-8ada-f20941f8eaca_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/94042756-2e7a-4cfa-812c-1b88b703eeea_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f6b4e686-8748-4d05-923a-f01662555cbb_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10196377","rdfs:label":"Weiler_FamilyA","estimatedLodScore":6.19,"family":{"id":"https://genegraph.clinicalgenome.org/r/f6b4e686-8748-4d05-923a-f01662555cbb","type":"Family","rdfs:label":"Weiler_FamilyA","member":{"id":"https://genegraph.clinicalgenome.org/r/5177c7a5-21ec-4eb4-b146-eb3b1621db8b"}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Two affected family members presented with Miyoshi Dystrophy, the other 7 patients had LGMD phenotype.","phenotypeNegativeAlleleNegative":11,"phenotypePositiveAllelePositive":9,"phenotypes":["obo:HP_0006785","obo:HP_0030115"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/5177c7a5-21ec-4eb4-b146-eb3b1621db8b"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c32963e8-8d23-4761-a6f9-d207ec51d525_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c32963e8-8d23-4761-a6f9-d207ec51d525","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","rdfs:label":"Nguyen_dysBE","allele":{"id":"https://genegraph.clinicalgenome.org/r/0549654c-bc74-40ae-93a5-57251ed618a6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001130987.2(DYSF):c.1488dup (p.Asp497ArgfsTer9)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA222127"}},"detectionMethod":"DNA extracted from peripheral blood lymphocytes was subject to PCR. All 55 exons including flanking regions were amplified. SSCP and dHPLC were used to detect abnormal products which were directly sequenced.","firstTestingMethod":"SSCP","phenotypes":["obo:HP_0003701","obo:HP_0002460"],"previousTestingDescription":"Patients were recruited to this study if their clinical phenotype was consistent with LGMD or distal myopathy. Loss or strong reduction of dysferlin expression evidenced by Western-blotting and/or immunohistochemistry on muscle biopsy was confirmed. If biopsy was unavailable, dysferlin deficiency in the sibship, and/or linkage to chromosome 2p13 was confirmed.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/db3d6732-12eb-4881-9163-a82c684dce50_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","allele":{"id":"https://genegraph.clinicalgenome.org/r/0549654c-bc74-40ae-93a5-57251ed618a6"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/db3d6732-12eb-4881-9163-a82c684dce50","type":"EvidenceLine","dc:description":"NMD expected, downgraded for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db3d6732-12eb-4881-9163-a82c684dce50_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/de4dd11b-4909-4402-91d9-2ae6f2a635e1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de4dd11b-4909-4402-91d9-2ae6f2a635e1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","rdfs:label":"Nguyen_dysZA","allele":{"id":"https://genegraph.clinicalgenome.org/r/6627b23b-f1c3-4445-9714-d34b8402745c"},"detectionMethod":"DNA extracted from peripheral blood lymphocytes was subject to PCR. All 55 exons including flanking regions were amplified. SSCP and dHPLC were used to detect abnormal products which were directly sequenced.","firstTestingMethod":"SSCP","phenotypeFreeText":"Proband was initially assessed as having \"pseudometabolic\" muscular dystrophy. Probnd experienced painful calf swelling without signs of weakness or atrophy at the beginning of the clinical course. Recurrent episodes of rhabdomyolysis with massive elevation of CK and dark urine following minimal exercise were reported.","phenotypes":["obo:HP_0003236","obo:HP_0003201"],"previousTesting":true,"previousTestingDescription":"Patients were recruited to this study if their clinical phenotype was consistent with LGMD or distal myopathy. Loss or strong reduction of dysferlin expression evidenced by Western-blotting and/or immunohistochemistry on muscle biopsy was confirmed. If biopsy was unavailable, dysferlin deficiency in the sibship, and/or linkage to chromosome 2p13 was confirmed.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/7b9e5a38-b193-471b-acc9-9d6bdd9afd4e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16010686","allele":{"id":"https://genegraph.clinicalgenome.org/r/6627b23b-f1c3-4445-9714-d34b8402745c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/7b9e5a38-b193-471b-acc9-9d6bdd9afd4e","type":"EvidenceLine","dc:description":"NMD expected, downgraded for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7b9e5a38-b193-471b-acc9-9d6bdd9afd4e_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/94042756-2e7a-4cfa-812c-1b88b703eeea_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94042756-2e7a-4cfa-812c-1b88b703eeea_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7969d214-6199-4df6-a411-a4ccbacf3684","type":"EvidenceLine","dc:description":"Calpain 3 is a gene that is likely to be strongly or definitively associated with LGMD. Therefore, the evidence is scored default points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8d307e34-9e34-43a1-a276-24db81cf965e","type":"Finding","dc:description":"Lysates from mouse myoblasts, cultured myotubes and skeletal muscle tissue were used to immunoprecipitate dysferlin protein complex. Interaction partners of dysferling that were validated by Western blot include Calpain 3, mutations in which also result in LGMD. Others include AHNAK, ANXA2, tubulin, affixin, DHPR. Several other interacting proteins have been reported, such as caveolin 3 (PMID: 11532985), TRIM72 (PMID: 19380584), affixin or Î²-Parvin (PMID: 15835269), annexin A1 and A2 (PMID: 16100712).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21079765","rdfs:label":"de Morree_Protein interactions","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/651ec042-a540-4302-a5f9-03b636fbd4eb","type":"EvidenceLine","dc:description":"Evidence not scored since membrane repair defect is not solely responsible for dystrophic changes in dysferlin-null muscles (Lostal2012, PMID:22666441).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/31ec2af7-7f83-48a8-9b02-394e5740feb9","type":"Finding","dc:description":"Abnormal membrane repair of injured muscle fibers is expected to lead to elevated serum kinase levels. However, it is important to note that the membrane repair defect is not solely responsible for dystrophic changes in dysferlin-null muscles, as expression of myoferlin or minidysferlin rescues the membrane defect without rescuing the histopathological changes on muscle sections (Lostal2012, PMID:22666441).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12736685","rdfs:label":"Bansal_membrane_repair","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/d631326c-9121-43ae-9c28-d6e85a83c4fd","type":"EvidenceLine","dc:description":"The evidence is not scored any points as the role of this function in the pathomechanism of dysferlinopathy is unclear. Based on expert review, the evidence is not scored.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0536d8cf-0f36-46da-ad07-73bf1b6467b8","type":"Finding","dc:description":"Patients with LGMD due to dysferlin mutations show similar cellular defects. PMID: 15677541: EM on muscle biopsies from 10 patients with dysferlinopathy, prominent aggregation of small vesicles consisting of empty, swollen cisternae in the subsarcolemmal region and many gaps and microvilli-like projections in the sarcolemma were seen.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12736685","rdfs:label":"Bansal_Membrane resealing function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/31edd059-7a43-49eb-ab4a-bfe42460d1ce","type":"EvidenceLine","dc:description":"Absent or severely decrease levels of dysferlin protein in muscle tissue is a typical feature of Autosomal recessive limb-girdle muscular dystrophy. This study describes a cohort of 65 LGMD/MM patients with â¤20% Dysferlin on Western Blot performed on muscle biopsies from these patients. Different pathogenic DYSF variants were reported as causal in this study. Since altered protein level is shown repeatedly in multiple patients with the disease regardless of the causative variant, this evidence is scored default points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/555fddc2-a13f-40b7-88a8-cfbdf5803469","type":"Finding","dc:description":"This study describes a cohort of 65 LGMD/MM patients with â¤20% Dysferlin on Western Blot performed on muscle biopsies from these patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21522182","rdfs:label":"Cacciottolo_65patients_expression","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/81aea755-b6e4-43f1-95b9-71d50a73f21e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/529cc369-7469-4ad0-afb7-f03187b27a5d","type":"Finding","dc:description":"Dysferlin expression in rat was found to be ubiquitous, with the strongest expressions in skeletal muscle, heart and kidney. Light microscopy and EM revealed localization of dysferlin to the periphery of myofibers, In LGMD2B patients, Western blot on muscle biopsies revealed reduced dysferlin levels (<5%), while levels in patients with other muscular dystrophies were similar to that seen in normal controls. (Also see PMID: 15535137)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10196375","rdfs:label":"Anderson_Expression","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9469aab0-3563-4ade-83f9-847ff45b48a3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/375ba2fe-64ff-4ec1-81c8-7bbe0055fe6d","type":"Finding","dc:description":"Pathogenic mutant forms of dysferlin are not able to participate in the biogenesis of the t-tubule-like system in vitro and in a non-muscle cell system. Moreover, human dysferlin-deficient myoblasts differentiated in culture into multinucleated fibers show abnormal compact tubular aggregates instead of the organized t-tubular system (Hofhuis2017 PMID: 28104817)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24302765","rdfs:label":"Kerr_t-tubule_function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/3a5b2b93-5a59-4df8-b427-43867317ab41","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/004a50f2-292b-4512-a36c-eae590860751","type":"Finding","dc:description":"Pathogenic variants in CAV3 are associated with Rippling Muscle Disease (RMD2, formerly LGMD1C). Dysferlin and caveolin3 co-precipitate from human muscle biopsy extracts using both anti-dysferlin and anti-caveolin3 antibodies. The study also shows that dysferlin staining pattern and intensity are abnormal in muscle sections from patients with pathogenic variants in CAV3.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11532985","rdfs:label":"Matsuda_CAV3_interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/94042756-2e7a-4cfa-812c-1b88b703eeea_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ba4d77ca-3abb-42ff-b592-0535ec443603","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2faa3604-6e4f-4917-822f-915d5b17ce87","type":"FunctionalAlteration","dc:description":"Dysferlin was found to localize to highly dynamic tubular and vesicular structures in the non-muscle cells, and that these were morphologically similar to the T-tubules in skeletal and cardiac muscles. None of the mutant dysferlins (except Arg1331Leu) induced membrane tubulation in non-muscle cells. Flotation experiments using liposomes revealed that only wild-type dysferlin bound to the membranes (WB), while none of the mutants did.\n\nIn addition, T-tubule biogenesis was studied in human dysferlin-deficient myoblasts, wherein highly compact tubular aggregates were observed in 36% of dysferlin-deficient fibers but not in control fibers. In a dysferlin-null mouse model, large vacuoles appeared within T-tubules during induced muscle regeneration.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28104817","rdfs:label":"Hofhuis_T-tubule organization"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/94042756-2e7a-4cfa-812c-1b88b703eeea_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4838ba45-0659-4df9-bd4d-7e4ddd9e19a8","type":"EvidenceLine","dc:description":"Expressing minidysferlin cDNA in muscle fibers of A/J mice restores the defective membrane resealing activity in these cells, as determined by an in vitro assay. However, the dystrophic features of muscle tissue at the histological level were not improved by expression of minidysferlin. Since only a limited number of muscle fibers received minidysferlin due to the localized vector injection, the global assessment of the phenotype, such as CK levels, was not possible. This evidence was scored a decreased number of 0.5 points.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9965f5b6-9caf-497b-9db8-041c1e0abfad","type":"Finding","dc:description":"A/J mice lacking Dysf expression (PMID:15254015) reproduce well human pathology, such as the typical dystrophic histopathological features in proximal muscles and elevated creatine kinase levels. Minidysferlin is a natural variant lacking exons 2-40 that was identified in a homozygous state in a mildly affected dysferlinopathy patient. This protein localizes normally within muscle fibers and is believed to at least partially retain its function, explaining the mildness of the muscle phenotype presented by the patient. Expressing minidysferlin cDNA in muscle fibers of A/J mice restores the defective membrane resealing activity in these cells. However, the dystrophic features of muscle tissue at the histological level were not improved by expression of minidysferlin.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20861509","rdfs:label":"Krahn_minidysferlin_rescue","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1191c863-8c63-43aa-824c-0b837279c2e2","type":"EvidenceLine","dc:description":"A/J mice lacking Dysf expression (PMID:15254015) reproduce well human pathology, such as the typical dystrophic histopathological features in proximal muscles and elevated creatine kinase levels. Expressing a full-length human DYSF cDNA in muscle cells of A/J mice rescued the muscle phenotype. This evidence was scored default points.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/066e1d07-4a28-479b-9550-fce0e40c674f","type":"Finding","dc:description":"Skeletal muscle disease in these mice was assessed at 8 months of age by quantification of common dystrophic parameters, such as central nucleation, fibrosis, distribution of myofiber cross-sectional areas, macrophage infiltration, as well as by testing functional recovery from injury, and total serum CK levels. A complete rescue of skeletal muscle histopathology and CK serum levels was observed at 8 months in Dysfâ/â mice that contained the Dysf-TG compared with Dysfâ/â alone. There was also improvement of functional recovery from injury to the ankle dorsiflexor muscles following 15 successive lengthening contractions.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19834057","rdfs:label":"Millay_human_cDNA_rescue","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/93fb59f5-bbf6-450d-85d9-c05ee7e17131","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/89928beb-dfec-400f-b9d3-963dbba81756","type":"Finding","dc:description":"The dysferlin-null mice develop a slowly progressive muscular dystrophy. The initial dystrophic changes were observed at the age of 2 months, progressing to the full spectrum of pathological characteristics of muscular dystrophy at 8 months (regenerating fibers, split fibers, muscle necrosis with macrophage infiltration and fat replacement). The severity of the pathology varied in different muscles of dysferlin-null mice. Plasma membrane disruptions were identified with a membrane-impermeant dye Evans blue. The creatine kinase levels of dysferlin-null mice were 6-fold higher than that of wild type mice.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12736685","rdfs:label":"Bansal_dysf_ko","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7b4bff72-f322-412e-aa7f-c415512c8773","type":"EvidenceLine","dc:description":"Score is reduced since rescue is not complete.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a368a460-f8ba-4f8b-bdb2-f527073b3434","type":"Finding","dc:description":"Rescue of membrane repair was evaluated using the level of penetration of Evans blue dye. 15 mice of ~9m of age were separated into 3 groups, each receiving HBSS (NC), plasmid encoding h-dysferlin and plasmid encoding dysferlin and follistatin. Western blot on muscles harvested after 1m showed that dysferlin levels in the therapeutic groups were similar or higher compared to that in wild-type mice, indicating there may be overexpression of dysferlin. IHC revealed an average 15% of dysferlin-positive fibers in the therapeutic group. In a 3-month study, 18 male mice (7mo) recieved reduced initial DNA dose. WB and densitometry revealed dysferlin levels similar to normal in the therapeutic groups. Evan's blue dye test showed decreased levels of dye penetration in mucles from treated mice. H&E staining revealed that those muscle fibers that expressed dysferlin showed a decrease in centronucleation, compared to others. When overall levels of centronucleation in muscle fibers from treated mice were evaluated, the average was not different from that seen in the untreated group.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31890729","rdfs:label":"Guha_Plasmid Rescue","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/494c01ff-238d-4ea8-a433-5422ab949956","type":"EvidenceLine","dc:description":"Note: PMID: 30439648 describes using antisense oligonucleotides to remove mutant exons in patient cell lines, which results in restoration of the membrane resealing ability.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ddcf26f4-c699-4edf-a9d7-c657e6223273","type":"Finding","dc:description":"Treatment of cultured myotubes with antisense oligonucleotides for 2d resulted in inhibition of expression of the mutant transcript (including pseudoexon), confirmed by qRT-PCR. Treatment with antisense oligonucleotides for 3d also restored DYSF protein expression to levels similar to normal myotubes, confirmed by Western blot.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31019989","rdfs:label":"Dominov_rescue in patient cells","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f8b92cb9-937d-43dd-af2c-74976e6502e4","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/772d6f1b-ed9d-4f1c-9df1-db56a6258703","type":"Finding","dc:description":"The skipping of exon 32 was confirmed RT-PCR. Immunostaining assays showed correct localization of quasi-dysferlin protein in patientsâ myotubes. Laser wounding assay showed the rescue of membrane repair defect in patient cells treated with AONs. The response to the mechanical stress was also normalized based on the results of the osmotic shock assay.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27858744","rdfs:label":"Barthelemy_rescuePatientCells","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/328e44ad-59bc-47a1-a192-17d87d89d7e6","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e60c534-6968-430f-b62c-775ee9262ac3","type":"Finding","dc:description":"Twenty eight weeks after systemic injection of the vector, widespread DYSF expression was observed in all skeletal muscles (with 31% of fibers transduced in the psoas muscle). Fiber size distribution was normalized in psoas muscle. There was a significant reduction in centralized nuclei in the reated tibialis anterior, quadricepts, tricepts and psoas muscles. There was also a significant reduction of CD8 cells in treated muscles (25.6 cells/mm3 in treated vs. 62.2cells/mm3 in untreated), as well as a significant reduction in collagen deposition in psoas muscles (9.7% treated vs. 37% untreated). Long-term benefits of intravenous gene transfer were also evident, as decrease in central nucleation, normalization of fiber diameters and reduction in fibrosis in the gluteus muscles were observed at 15 months post injection.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28707952","rdfs:label":"Potter_rescue_dualAAV","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/2e86bd24-f7cb-4afa-8463-f4a4954e02ef","type":"EvidenceLine","dc:description":"The evidence is scored increased points since the human phenotype is recapitulated by two distinct dysferlin-deficient mouse models.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a4deb87-0247-46d5-aba9-3790b3f77c81","type":"Finding","dc:description":"Immunofluorescence and western blot analysis showed the absence of dysferlin in skeletal muscles in Dysf-ko and A/J mice, while it was present in wild-type and heterozygous mice. In Dysf-ko mice, H&E stained section of proximal muscles (quadriceps femoris and triceps brachii) showed increased numbers of necrotic and regenerating fibers, infiltration of mononuclear cells into intact fibers, phagocytosis, marked variation of fiber size, hypertrophic fibers, fiber splitting and fat replacement, followed by later and milder involvement of distal muscles (gastrocnemius, soleus and tibialis anterior). Similar findings were also observed in A/J mice. Serum creatine kinase was elevated in both Dysf-ko and A/J mice compared to age-matched wild-type and heterozygous mice. Sarcolemma integrity of dysferlin-deficient mice was also shown to be compromised. The muscular dystrophy worsened with age in dysferlin-deficient mice.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15254015","rdfs:label":"Ho_DYSFko_A/J","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":9343,"specifiedBy":"GeneValidityCriteria11","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/0B-QL7DtBkU","type":"GeneValidityProposition","disease":"obo:MONDO_0015152","gene":"hgnc:3097","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_94042756-2e7a-4cfa-812c-1b88b703eeea-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}